Race Oncology Limited - RAC share price
About
Race Oncology Limited is an Australian precision oncology company. They're developing a cancer drug called Zantrene, which targets the FTO protein. Zantrene is being explored as a potential therapy for melanoma and clear cell renal cell carcinoma, both linked to FTO. It acts as a precise, low-dose oncology agent and a cardio-protective chemotherapeutic. The drug also shows promise in reducing cardiotoxicity in acute myeloid leukemia, breast, and ovarian cancers. Race Oncology is dedicated to advancing Zantrene as a cancer treatment with a focus on improving chemotherapy outcomes.
Company Profile
Disclaimer: The above financial data is sourced from EODHD and is for informational purposes only. Veye does not guarantee the accuracy or completeness of this data. Investors should conduct their own research and consult with a financial advisor before making investment decisions.
Price Summary
Price Chart
Get Your FREE Report
Discover the Top ASX Stocks to Invest In 2026!
Expert Analysis of Top-Performing ASX Stocks
Market Insights and In-Depth Research
Buy, Sell, And Hold Recommendations
Almost There!
Enter your details to download the report
Success!
Preparing your download...
Latest Reports from Veye
Grab Your FREE Report on Top 5 ASX Stocks to Buy in 2026
Latest Article
